---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Indication questions"
description: "Indication questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Eligibility and Testing. Questions: What is Nucala approved for in asthma? Can Nucala treat an acute asthma attack? Which severe asthma patients may be candidates for Nucala? What blood eosinophil count was linked to Nucala benefit in severe asthma trials? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Indication questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Indication questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Indication](https://www.evicenter.com/medical-information/nucala/indication).

## Indication

<a id="nucala-indication"></a>

### What is Nucala approved for in asthma?

> “NUCALA is indicated for the:”

Source: [NUCALA: Learn About an SEA Treatment Option, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/#:~:text=NUCALA%20is%20indicated%20for%20the%3A)

> “add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.”

Source: [NUCALA: Learn About an SEA Treatment Option, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/#:~:text=add%2Don%20maintenance%20treatment%20of%20adult,acute%20bronchospasm%20or%20status%20asthmaticus.)

<a id="nucala-acute-asthma-attacks"></a>

### Can Nucala treat an acute asthma attack?

> “Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease
>
> NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.”

Source: [NUCALA: Learn About an SEA Treatment Option, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/#:~:text=Acute%20Symptoms%20of%20Asthma%20or,or%20COPD%2C%20or%20acute%20bronchospasm.)

> “Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should 
> seek medical advice if their asthma or COPD remains uncontrolled or worsens after initiation of 
> treatment with NUCALA.”

Source: [NUCALA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=6)

## Eligibility

<a id="nucala-candidate-patients"></a>

### Which severe asthma patients may be candidates for Nucala?

> “UNCONTROLLED SEVERE ASTHMA WITH AN EOSINOPHILIC PHENOTYPE
>
> Uncontrolled severe asthma: 2 or more exacerbations* in the previous 12 months and/or daily OCS despite being on high-dose ICS<sup>†</sup> plus a controller
>
> Eosinophilic phenotype: Baseline blood eosinophils ≥150 cells/µL, a key marker of type 2 inflammation”

Source: [NUCALA: SEA Patient Types, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/patient-types/#:~:text=UNCONTROLLED%20SEVERE%20ASTHMA%20WITH%20AN,marker%20of%20type%202%20inflammation)

> “*Defined as worsening of asthma requiring: systemic corticosteroids or hospitalization or ED visit; or at least double the existing maintenance systemic corticosteroid dose for ≥3 days.
>
> <sup>†</sup>High-dose ICS in patients aged ≥18 years; medium- to high-dose ICS in patients aged ≥6 years.”

Source: [NUCALA: SEA Patient Types, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/patient-types/#:~:text=%2ADefined%20as%20worsening%20of%20asthma,in%20patients%20aged%20%E2%89%A56%20years.)

Note: This is the manufacturer's description of the patient type. The label's indication statement does not give a blood eosinophil count.

## Testing

<a id="nucala-eosinophil-threshold"></a>

### What blood eosinophil count was linked to Nucala benefit in severe asthma trials?

> “In these 2 trials patients were required to have blood eosinophils of ≥150 cells/mcL at 
> screening (within 6 weeks of dosing) or blood eosinophils of ≥300 cells/mcL within 12 months 
> of enrollment. The screening blood eosinophils of ≥150 cells/mcL criterion was derived from 
> exploratory analyses of data from the DREAM Trial.”

Source: [NUCALA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=21)

> “DREAM data were explored to determine criteria that could identify patients likely to benefit 
> from treatment with NUCALA. The exploratory analysis suggested that baseline blood 
> eosinophil count of ≥150 cells/mcL was a potential predictor of treatment benefit. Exploratory 
> analysis of MENSA data also suggested that baseline blood eosinophil count (obtained within 
> 6 weeks of initiation of dosing) of ≥150 cells/mcL was a potential predictor of efficacy and 
> showed a trend of greater exacerbation benefit with increasing blood eosinophil count. In 
> MENSA, patients enrolled solely on the basis of the historical blood eosinophil count of 
> ≥300 cells/mcL in the previous 12 months, but who had a baseline blood eosinophil count 
> <150 cells/mcL, had virtually no exacerbation benefit following treatment with NUCALA 
> 100 mg compared with placebo.”

Source: [NUCALA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=23)

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
